Biotech · Private company
Denovo Biopharma LLC
Track this companyFree. Adds Denovo Biopharma LLC to your Dealase workspace and tells you when its record changes.
Clinical trials152 recruiting or active
Pipeline programs13From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline13
- AripiprazolePhase 3 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- Enzastaurin HydrochloridePhase 3 · Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- Enzastaurin HydrochloridePhase 3 · GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026
- LY2140023Phase 3 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- OlanzapinePhase 3 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- Pomaglumetad methionilPhase 3 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- QuetiapinePhase 3 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- RadiotherapyPhase 3 · GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026
- RisperidonePhase 3 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- TemozolomidePhase 3 · GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026
- LiafensinePhase 2 · Treatment Resistant DepressionClinicalTrials.gov · fetched Nov 12, 2026
- LY2140023Phase 1 · Schizophrenic DisordersClinicalTrials.gov · fetched Nov 12, 2026
- MoxifloxacinPhase 1 · Schizophrenic DisordersClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials15
- DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade GliomaPHASE1_PHASE2 · RECRUITING · started Jan 8, 2025ClinicalTrials.gov NCT06504381 · fetched Nov 12, 2026
- DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic AstrocytomaPHASE2 · RECRUITING · started May 1, 2024ClinicalTrials.gov NCT06264388 · fetched Nov 12, 2026
- A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRDPHASE2 · COMPLETED · started Jun 29, 2022ClinicalTrials.gov NCT05113771 · fetched Nov 12, 2026
- A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1PHASE3 · COMPLETED · started Dec 16, 2020ClinicalTrials.gov NCT03776071 · fetched Nov 12, 2026
- Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™PHASE3 · COMPLETED · started Mar 20, 2018ClinicalTrials.gov NCT03263026 · fetched Nov 12, 2026
- A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With SchizophreniaPHASE1 · COMPLETED · started Jun 1, 2012ClinicalTrials.gov NCT01606436 · fetched Nov 12, 2026
- A Long-Term Safety Study of Pomaglumetad Methionil in SchizophreniaPHASE3 · TERMINATED · started Dec 1, 2011ClinicalTrials.gov NCT01487083 · fetched Nov 12, 2026
- A Physical Dependence Study in SchizophreniaPHASE3 · COMPLETED · started Nov 1, 2011ClinicalTrials.gov NCT01452919 · fetched Nov 12, 2026
- A Study of Safety and Tolerability in Subjects With SchizophreniaPHASE1 · COMPLETED · started May 1, 2011ClinicalTrials.gov NCT01354353 · fetched Nov 12, 2026
- A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia PatientsPHASE3 · TERMINATED · started Apr 1, 2011ClinicalTrials.gov NCT01328093 · fetched Nov 12, 2026
- A Study of LY2140023 in Patients With SchizophreniaPHASE3 · TERMINATED · started Mar 1, 2011ClinicalTrials.gov NCT01307800 · fetched Nov 12, 2026
- A Long-Term, Open-Label, Study on SchizophreniaPHASE2_PHASE3 · TERMINATED · started Jun 1, 2010ClinicalTrials.gov NCT01129674 · fetched Nov 12, 2026
- A Comparator Study of LY2140023 Versus Placebo in Schizophrenia PatientsPHASE2 · COMPLETED · started Mar 1, 2010ClinicalTrials.gov NCT01086748 · fetched Nov 12, 2026
- A Study of LY2140023 in Schizophrenia Patients With Prominent Negative SymptomsPHASE2 · COMPLETED · started Jan 1, 2010ClinicalTrials.gov NCT01052103 · fetched Nov 12, 2026
- A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic PatientsPHASE2 · COMPLETED · started Mar 1, 2009ClinicalTrials.gov NCT00845026 · fetched Nov 12, 2026